The primary endpoint or secondary endpoints did not reach statistical significance as measured by change from baseline in the Revised ALSFRS (ALSFRS-R) or ALSAQ-40 and SVC, despite with good tolerance and safety.
← all excerpts
Current and emerging therapeutic strategies for amyotrophic lateral sclerosis: from pharmacological approaches to gene and stem cell therapies.
1
—
—